Company Overview
NewLink is an emerging biopharmaceutical company focused on discovery and development of novel, immunotherapeutic agents. Our mission is to achieve breakthrough improvements in the survival and quality-of-life of cancer patients.
We are currently advancing four product candidates in human clinical trials. Our HyperAcute® immunotherapies for treatment of pancreatic cancer and non-small cell lung cancer are moving forward in Phase 2 efficacy studies, while the HyperAcute product for melanoma is showing early promise in a small, investigator-sponsored Phase 2 study. We are also developing a first-in-class, small-molecule inhibitor of the IDO* pathway, which is presently undergoing Phase 1 testing for safety.
NewLink's scientific team combines extensive backgrounds in cancer biology, immunology, infectious disease, and molecular genetics, including a decade of professional collaboration among its senior leadership in work conducted at the National Cancer Institute and the National Human Genome Research Institute prior to the company's founding in 1999. Based in Ames, Iowa, NewLink has approximately 60 employees, with over 20 holding MD, PhD, or both degrees.
* indoleamine 2,3 dioxygenase